CL2014001486A1 - Compuestos derivados de urea, inhibidores de quinasa; composicion farmaceutica que los comprende; uso en el tratamiento de enfermedades tales como neumonia eosinofilica cronica, asma, copd, sindrome de angustia respiratoria en adultos (ards), entre otras. - Google Patents
Compuestos derivados de urea, inhibidores de quinasa; composicion farmaceutica que los comprende; uso en el tratamiento de enfermedades tales como neumonia eosinofilica cronica, asma, copd, sindrome de angustia respiratoria en adultos (ards), entre otras.Info
- Publication number
- CL2014001486A1 CL2014001486A1 CL2014001486A CL2014001486A CL2014001486A1 CL 2014001486 A1 CL2014001486 A1 CL 2014001486A1 CL 2014001486 A CL2014001486 A CL 2014001486A CL 2014001486 A CL2014001486 A CL 2014001486A CL 2014001486 A1 CL2014001486 A1 CL 2014001486A1
- Authority
- CL
- Chile
- Prior art keywords
- ards
- copd
- adults
- asthma
- urea
- Prior art date
Links
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 title 1
- 208000016300 Idiopathic chronic eosinophilic pneumonia Diseases 0.000 title 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 title 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 title 1
- 208000006673 asthma Diseases 0.000 title 1
- 239000004202 carbamide Substances 0.000 title 1
- 201000009323 chronic eosinophilic pneumonia Diseases 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 229940043355 kinase inhibitor Drugs 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
- C07C53/02—Formic acid
- C07C53/06—Salts thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/38—Nitrogen atoms
- C07D231/40—Acylated on said nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Pulmonology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11192871 | 2011-12-09 | ||
| EP12187931 | 2012-10-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2014001486A1 true CL2014001486A1 (es) | 2014-11-14 |
Family
ID=47471708
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2014001486A CL2014001486A1 (es) | 2011-12-09 | 2014-06-06 | Compuestos derivados de urea, inhibidores de quinasa; composicion farmaceutica que los comprende; uso en el tratamiento de enfermedades tales como neumonia eosinofilica cronica, asma, copd, sindrome de angustia respiratoria en adultos (ards), entre otras. |
Country Status (34)
| Country | Link |
|---|---|
| US (5) | US8907094B2 (es) |
| EP (1) | EP2788349B1 (es) |
| JP (1) | JP6128449B2 (es) |
| KR (1) | KR101994381B1 (es) |
| CN (3) | CN104039787B (es) |
| AR (1) | AR089189A1 (es) |
| AU (1) | AU2012347350C1 (es) |
| BR (1) | BR112014013760A2 (es) |
| CA (1) | CA2858447C (es) |
| CL (1) | CL2014001486A1 (es) |
| CO (1) | CO6970602A2 (es) |
| CY (1) | CY1118340T1 (es) |
| DK (1) | DK2788349T3 (es) |
| EA (1) | EA025268B1 (es) |
| ES (1) | ES2612259T3 (es) |
| GE (1) | GEP201706735B (es) |
| HR (1) | HRP20161714T1 (es) |
| HU (1) | HUE029826T2 (es) |
| IL (1) | IL232958A (es) |
| LT (1) | LT2788349T (es) |
| ME (1) | ME02624B (es) |
| MX (1) | MX359200B (es) |
| MY (1) | MY170656A (es) |
| PE (1) | PE20141370A1 (es) |
| PH (1) | PH12014501277A1 (es) |
| PL (1) | PL2788349T3 (es) |
| PT (1) | PT2788349T (es) |
| RS (1) | RS55602B1 (es) |
| SG (1) | SG11201402985VA (es) |
| SI (1) | SI2788349T1 (es) |
| TW (1) | TWI618703B (es) |
| UA (1) | UA115320C2 (es) |
| WO (1) | WO2013083604A1 (es) |
| ZA (1) | ZA201404156B (es) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112014013178A2 (pt) * | 2011-12-09 | 2017-06-13 | Chiesi Farm Spa | composto, composição farmacêutica e uso de um composto |
| WO2013083606A1 (en) * | 2011-12-09 | 2013-06-13 | Chiesi Farmaceutici S.P.A. | Kinase inhibitors |
| MY170656A (en) * | 2011-12-09 | 2019-08-24 | Chiesi Farm Spa | Kinase inhibitors |
| GB201214750D0 (en) | 2012-08-17 | 2012-10-03 | Respivert Ltd | Compounds |
| WO2014033447A2 (en) | 2012-08-29 | 2014-03-06 | Respivert Limited | Kinase inhibitors |
| US20150210722A1 (en) | 2012-08-29 | 2015-07-30 | Respivert Limited | Kinase inhibitors |
| WO2014033449A1 (en) | 2012-08-29 | 2014-03-06 | Respivert Limited | Kinase inhibitors |
| US9732063B2 (en) | 2012-11-16 | 2017-08-15 | Respivert Limited | Kinase inhibitors |
| US20160016934A1 (en) | 2013-03-14 | 2016-01-21 | Respivert Limited | Kinase inhibitors |
| EP2981535B8 (en) | 2013-04-02 | 2021-03-10 | Oxular Acquisitions Limited | Urea derivatives useful as kinase inhibitors |
| EP2981534B1 (en) | 2013-04-02 | 2017-07-19 | Topivert Pharma Limited | Kinase inhibitors based upon n-alkyl pyrazoles |
| HK1219101A1 (zh) | 2013-06-06 | 2017-03-24 | 奇斯药制品公司 | 作为p38map激酶抑制剂的[1，2，4]三唑并[4，3-a]吡啶的衍生物 |
| BR112015029462A8 (pt) * | 2013-06-06 | 2023-03-21 | Chiesi Farm Spa | Inibidores de quinase |
| BR112015029970A2 (pt) | 2013-06-06 | 2017-07-25 | Chiesi Farm Spa | inibidores de cinase |
| EP2818471A1 (en) * | 2013-06-27 | 2014-12-31 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Nitrogen bicyclic compounds as inhibitors for Scyl1 and Grk5 |
| JP6514703B2 (ja) | 2013-12-20 | 2019-05-15 | トピバート ファーマ リミテッド | キナーゼインヒビターとして有用な尿素誘導体 |
| EA034927B1 (ru) | 2014-02-14 | 2020-04-07 | Респайверт Лимитед | Ароматические гетероциклические соединения как противовоспалительные соединения |
| MA40774A (fr) | 2014-10-01 | 2017-08-08 | Respivert Ltd | Dérivés de diaryle-urée en tant qu'inhibiteurs de kinase p38 |
| US10206949B2 (en) | 2015-09-21 | 2019-02-19 | Ofer Agam | Composition that relieves heartburn, GERD and hangovers |
| AR107164A1 (es) | 2015-12-23 | 2018-03-28 | Chiesi Farm Spa | INHIBIDORES DE QUINASA p38 |
| TW201730189A (zh) | 2015-12-23 | 2017-09-01 | 吉斯藥品公司 | 激酶抑制劑 |
| EP3394058B1 (en) | 2015-12-23 | 2020-10-14 | Chiesi Farmaceutici S.p.A. | N-[3-(3-{4-[[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl} -ureido)-phenyl]-methanesulfonamide derivatives and their use as p38 mapk inhibitors |
| KR102387073B1 (ko) | 2016-04-06 | 2022-04-15 | 옥슬러 액퀴지션즈 리미티드 | 키나제 저해제 |
| US10364245B2 (en) * | 2017-06-07 | 2019-07-30 | Chiesi Farmaceutici S.P.A. | Kinase inhibitors |
| RS63581B1 (sr) | 2017-10-05 | 2022-10-31 | Fulcrum Therapeutics Inc | Inhibitori p38 kinaze smanjuju ekspresiju dux4 i nizvodnih gena u cilju lečenja fshd |
| US10342786B2 (en) | 2017-10-05 | 2019-07-09 | Fulcrum Therapeutics, Inc. | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD |
| CN108424372B (zh) * | 2018-05-11 | 2021-08-10 | 浙江华贝药业有限责任公司 | 2，2，2-三氟-n-[(s)-4-羰基四氢萘-1-基]-乙酰胺的纯化工艺 |
| CN108707086B (zh) * | 2018-05-15 | 2021-08-10 | 浙江华贝药业有限责任公司 | 一种(1s，4s)-n-（4-羟基四氢萘-1-基）叔丁氧基碳酰胺的纯化工艺 |
| AR116628A1 (es) | 2018-10-18 | 2021-05-26 | Syngenta Crop Protection Ag | Compuestos microbiocidas |
| WO2021176007A1 (en) | 2020-03-05 | 2021-09-10 | Syngenta Crop Protection Ag | Fungicidal compositions |
| CN112174870B (zh) * | 2020-10-12 | 2023-07-21 | 蔡霈 | (r)-1-烷烃酰基-2-取代吡咯烷-2-甲酰胺的制备方法及其药用用途 |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU650953B2 (en) | 1991-03-21 | 1994-07-07 | Novartis Ag | Inhaler |
| US5756533A (en) | 1995-03-10 | 1998-05-26 | G.D. Searle & Co. | Amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors |
| US6034057A (en) | 1995-07-06 | 2000-03-07 | Zeneca Limited | Peptide inhibitors of fibronectine |
| US6248713B1 (en) | 1995-07-11 | 2001-06-19 | Biogen, Inc. | Cell adhesion inhibitors |
| YU25500A (sh) | 1999-05-11 | 2003-08-29 | Pfizer Products Inc. | Postupak za sintezu analoga nukleozida |
| GB0028383D0 (en) | 2000-11-21 | 2001-01-03 | Novartis Ag | Organic compounds |
| EP1241176A1 (en) | 2001-03-16 | 2002-09-18 | Pfizer Products Inc. | Purine derivatives for the treatment of ischemia |
| CA2443697A1 (en) * | 2001-04-13 | 2002-10-24 | Pier F. Cirillo | 1,4-disubstituted benzo-fused compounds |
| ES2271365T3 (es) | 2001-12-20 | 2007-04-16 | Bayer Healthcare Ag | Derivados de 1,4-dihidro-1,4-difenilpiridina. |
| WO2004014870A1 (en) * | 2002-08-08 | 2004-02-19 | Boehringer Ingelheim Pharmaceuticals, Inc. | Fluorinated phenyl-naphthalenyl-urea compounds as inhibitors of cytokines involved in inflammatory processes |
| BRPI0407384A (pt) | 2003-02-14 | 2006-02-21 | Pfizer Prod Inc | piridinas-triazóis como compostos antiinflamatórios |
| SE0302487D0 (sv) | 2003-09-18 | 2003-09-18 | Astrazeneca Ab | Novel compounds |
| EP1751136B1 (en) * | 2004-05-07 | 2014-07-02 | Amgen Inc. | Nitrogenated heterocyclic derivatives as protein kinase modulators and use for the treatment of angiogenesis and cancer |
| EP1609789A1 (en) | 2004-06-23 | 2005-12-28 | Eli Lilly And Company | Ureido-pyrazole derivatives and their use as kinase inhibitors |
| PL1761520T3 (pl) | 2004-06-23 | 2008-12-31 | Lilly Co Eli | Inhibitory kinazy |
| PL1778686T3 (pl) | 2004-08-12 | 2009-04-30 | Pfizer | Pochodne triazolopirydynylosulfanylowe jako inhibitory kinazy MAP P38 |
| GB0418015D0 (en) * | 2004-08-12 | 2004-09-15 | Pfizer Ltd | New compounds |
| US20090215817A1 (en) | 2004-08-18 | 2009-08-27 | Pfizer Inc | Novel Triazolopyridine Compounds for the Treatment of Inflammation |
| GB0502258D0 (en) | 2005-02-03 | 2005-03-09 | Argenta Discovery Ltd | Compounds and their use |
| EP1891047A4 (en) | 2005-06-03 | 2008-07-09 | Bayer Healthcare Ag | A 1-METHYL-1H-PYRAZOLE-4-CARBOXYLIC ACID SUITABLE FOR THE CHEMOTHERAPY OF CANCER |
| CA2642209A1 (en) * | 2006-02-09 | 2007-08-16 | Pfizer Limited | Triazolopyridine compounds |
| CN101146029B (zh) * | 2006-09-13 | 2011-12-28 | 华为技术有限公司 | 一种分组重排序方法和系统 |
| US8188113B2 (en) | 2006-09-14 | 2012-05-29 | Deciphera Pharmaceuticals, Inc. | Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases |
| WO2008043019A1 (en) | 2006-10-04 | 2008-04-10 | Pharmacopeia, Inc | 8-substituted 2-(benzimidazolyl) purine derivatives for immunosuppression |
| EP2068869A4 (en) | 2006-10-06 | 2011-05-25 | Abbott Lab | NEW IMIDAZOTHIAZOLE AND IMIDAZOXAZOLE |
| WO2008125014A1 (fr) | 2007-04-13 | 2008-10-23 | Institute Of Pharmacology And Toxicology Academy Of Military Medical Sciences P.L.A. | Composés d'urée, leurs procédés de préparation et leurs utilisations pharmaceutiques |
| WO2009015000A1 (en) | 2007-07-25 | 2009-01-29 | Array Biopharma Inc. | Pyrazole urea derivatives used as kinase inhibitors |
| CA2695636A1 (en) | 2007-08-10 | 2009-02-19 | Astellas Pharma Inc. | Bicyclic acylguanidine derivative |
| TWI496779B (zh) | 2008-08-19 | 2015-08-21 | Array Biopharma Inc | 作為ｐｉｍ激酶抑制劑之三唑吡啶化合物 |
| AU2009325133B2 (en) | 2008-12-08 | 2016-02-04 | Gilead Connecticut, Inc. | Imidazopyrazine Syk inhibitors |
| MX2011006220A (es) * | 2008-12-11 | 2011-06-28 | Respivert Ltd | Inhibidores de la proteina cinasa activada por el mitogeno p38. |
| WO2010077836A2 (en) | 2009-01-05 | 2010-07-08 | Boehringer Ingelheim International Gmbh | Pyrrolidine compounds which modulate the cb2 receptor |
| AU2010215261A1 (en) * | 2009-02-17 | 2011-09-08 | Chiesi Farmaceutici S.P.A. | Triazolopyridine derivatives as p38 MAP kinase inhibitors |
| WO2010108058A2 (en) | 2009-03-20 | 2010-09-23 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Small molecule inhibitors of dusp6 and uses therefor |
| WO2011018916A1 (ja) | 2009-08-12 | 2011-02-17 | コニカミノルタホールディングス株式会社 | 表示パネルの製造方法 |
| EP2308866A1 (de) | 2009-10-09 | 2011-04-13 | Bayer CropScience AG | Phenylpyri(mi)dinylpyrazole und ihre Verwendung als Fungizide |
| GB0921731D0 (en) | 2009-12-11 | 2010-01-27 | Respivert Ltd | Theraputic uses |
| GB201005589D0 (en) * | 2010-04-01 | 2010-05-19 | Respivert Ltd | Novel compounds |
| JP5787977B2 (ja) * | 2010-04-08 | 2015-09-30 | レスピバート・リミテツド | Ｐ３８ｍａｐキナーゼ阻害剤 |
| GB201009731D0 (en) * | 2010-06-10 | 2010-07-21 | Pulmagen Therapeutics Inflamma | Kinase inhibitors |
| MY170656A (en) | 2011-12-09 | 2019-08-24 | Chiesi Farm Spa | Kinase inhibitors |
| WO2013083606A1 (en) | 2011-12-09 | 2013-06-13 | Chiesi Farmaceutici S.P.A. | Kinase inhibitors |
| BR112014013178A2 (pt) | 2011-12-09 | 2017-06-13 | Chiesi Farm Spa | composto, composição farmacêutica e uso de um composto |
| BR112015029462A8 (pt) | 2013-06-06 | 2023-03-21 | Chiesi Farm Spa | Inibidores de quinase |
| HK1219101A1 (zh) | 2013-06-06 | 2017-03-24 | 奇斯药制品公司 | 作为p38map激酶抑制剂的[1，2，4]三唑并[4，3-a]吡啶的衍生物 |
| BR112015029970A2 (pt) | 2013-06-06 | 2017-07-25 | Chiesi Farm Spa | inibidores de cinase |
-
2012
- 2012-12-05 MY MYPI2014001662A patent/MY170656A/en unknown
- 2012-12-05 KR KR1020147018237A patent/KR101994381B1/ko not_active Expired - Fee Related
- 2012-12-05 CN CN201280066480.0A patent/CN104039787B/zh not_active Expired - Fee Related
- 2012-12-05 DK DK12809140.2T patent/DK2788349T3/en active
- 2012-12-05 CA CA2858447A patent/CA2858447C/en not_active Expired - Fee Related
- 2012-12-05 CN CN201610333320.8A patent/CN105968110B/zh not_active Expired - Fee Related
- 2012-12-05 EA EA201490949A patent/EA025268B1/ru unknown
- 2012-12-05 PL PL12809140T patent/PL2788349T3/pl unknown
- 2012-12-05 CN CN201510853733.4A patent/CN105503861B/zh not_active Expired - Fee Related
- 2012-12-05 SG SG11201402985VA patent/SG11201402985VA/en unknown
- 2012-12-05 HR HRP20161714TT patent/HRP20161714T1/hr unknown
- 2012-12-05 SI SI201230806A patent/SI2788349T1/sl unknown
- 2012-12-05 AU AU2012347350A patent/AU2012347350C1/en not_active Ceased
- 2012-12-05 MX MX2014006724A patent/MX359200B/es active IP Right Grant
- 2012-12-05 BR BR112014013760A patent/BR112014013760A2/pt not_active Application Discontinuation
- 2012-12-05 LT LTEP12809140.2T patent/LT2788349T/lt unknown
- 2012-12-05 ME MEP-2016-279A patent/ME02624B/me unknown
- 2012-12-05 JP JP2014545229A patent/JP6128449B2/ja not_active Expired - Fee Related
- 2012-12-05 HU HUE12809140A patent/HUE029826T2/en unknown
- 2012-12-05 GE GEAP201213495A patent/GEP201706735B/en unknown
- 2012-12-05 ES ES12809140T patent/ES2612259T3/es active Active
- 2012-12-05 PE PE2014000923A patent/PE20141370A1/es active IP Right Grant
- 2012-12-05 PT PT128091402T patent/PT2788349T/pt unknown
- 2012-12-05 UA UAA201406293A patent/UA115320C2/uk unknown
- 2012-12-05 WO PCT/EP2012/074446 patent/WO2013083604A1/en not_active Ceased
- 2012-12-05 EP EP12809140.2A patent/EP2788349B1/en active Active
- 2012-12-05 RS RS20170046A patent/RS55602B1/sr unknown
- 2012-12-07 TW TW101146036A patent/TWI618703B/zh not_active IP Right Cessation
- 2012-12-07 AR ARP120104598A patent/AR089189A1/es not_active Application Discontinuation
- 2012-12-07 US US13/708,324 patent/US8907094B2/en not_active Expired - Fee Related
-
2014
- 2014-06-05 IL IL232958A patent/IL232958A/en active IP Right Grant
- 2014-06-05 CO CO14121392A patent/CO6970602A2/es unknown
- 2014-06-06 ZA ZA2014/04156A patent/ZA201404156B/en unknown
- 2014-06-06 PH PH12014501277A patent/PH12014501277A1/en unknown
- 2014-06-06 CL CL2014001486A patent/CL2014001486A1/es unknown
- 2014-07-14 US US14/330,145 patent/US9145413B2/en not_active Expired - Fee Related
- 2014-10-14 US US14/513,663 patent/US9139584B2/en not_active Expired - Fee Related
-
2015
- 2015-08-06 US US14/819,722 patent/US9315503B2/en not_active Expired - Fee Related
-
2016
- 2016-04-18 US US15/131,401 patent/US9527846B2/en not_active Expired - Fee Related
- 2016-12-08 CY CY20161101269T patent/CY1118340T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2014001486A1 (es) | Compuestos derivados de urea, inhibidores de quinasa; composicion farmaceutica que los comprende; uso en el tratamiento de enfermedades tales como neumonia eosinofilica cronica, asma, copd, sindrome de angustia respiratoria en adultos (ards), entre otras. | |
| CL2014002093A1 (es) | Compuestos derivados piperidinopirimidinicos; composicion farmaceutica que los comprende; uso en el tratamiento de infecciones viricas. | |
| CL2014002915A1 (es) | Compuestos derivados de imidazotiadiazol e imidazopirazina, como inhibidores del receptor activado de proteasa 4 (par4); composicion farmaceutica que los comprende; y su uso para inhibir o prevenir la agregacion plaquetaria y por lo tanto utiles en el tratamiento de un trastorno tromboembolico o para la profilaxis primaria o secundaria de un trastorno tromboembolico. | |
| CL2015001731A1 (es) | Compuestos inhibidores de autotaxina; composicion y combinacion farmaceutica; y uso en el tratamiento de enfermedades tales como fibrosis, prurito, cancer, entre otras. | |
| CL2014002732A1 (es) | Compuestos derivados de imidazolil-pirimidinas sustituidas con amino-indolilo, inhibidores de la proteina quinasa syk; compuestos intermediarios; formulaciones farmaceuticas que los contienen; uso en el tratamiento de enfermedades tales como asma, epoc, rinitis alergica, entre otras. | |
| CL2014000511A1 (es) | Compuestos derivados de quinazolina, inhibidores selectivos y reversibles de la proteasa especifica de ubiquitina 7; proceso de preparacion; composiciones farmaceuticas que los contienen y el uso en el tratamiento y/o la prevencion de enfermedades tales como cancer. | |
| CL2015000956A1 (es) | Compuestos derivados de pirrolotriazinona como inhibidores de pi3k; composicion farmaceutica que los comprende; combinacion farmaceutica; uso para tratar enfermedades respiratorias, autoinmunes, trastornos neurologicos, cardiovasculares, metabolicos, entre otros. | |
| CL2014002726A1 (es) | Compuestos derivados de pirrolopirimidina y purina; composicion farmaceutica; utiles en el tratamiento del cancer (div. sol. 566-14). | |
| CL2015000256A1 (es) | Compuestos heteroaromáticos, inhibidores de btk, composicion farmaceutica que los comprende y uso en enfermedades tales como artritis reumatoide, lupus, entre otras. | |
| CL2014001829A1 (es) | Compuestos derivados de indolizina; procedimiento de preparación; composiciones farmacéuticas que los contienen y uso en el tratamiento del cancer. | |
| CR20160033A (es) | Inhibidores de autotaxina que comprenden un nucleo ciclico de anillo heteroaromático-bencil-amida | |
| CL2013002063A1 (es) | Compuestos derivados de pirrolo(piridina, pirimidina o pirazina), inhibidores de serina/trionina cinasa; composicion farmaceutica que los comprende; y su uso en el tratamiento del cancer, infecciones inflamaciones y enfermedades autoinmune. | |
| CL2014003136A1 (es) | Nuevos diazaespirocicloalcanos y azaespirocicloalcanos; composicion farmaceutica que los contiene y usos. | |
| CL2016001543A1 (es) | Derivados del isocromeno como inhibidores de las fosfoinositido-3 quinasas. | |
| IL230881A0 (en) | Preparations for pulmonary administration containing a eutectic mixture | |
| CL2014002386A1 (es) | Compuesto inhibidor de cinasa de fosfoinositida 3 en forma anhidra cristalina solida; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento o prevencion de enfermedades tales como epoc, asma, entre otras. | |
| CL2014001752A1 (es) | Compuestos biciclicos sustituidos; composicion farmaceutica que los comprende; y uso en el tratamiento de enfermedades tales como cancer, alzheimer, sida, entre otras. | |
| DOP2013000192A (es) | Compuestos y composiciones como inhibidores de la trk | |
| CL2013002939A1 (es) | Compuestos derivados de nucleosidos 2´-sustituidos , inhibidores ns5a; composicion farmaceutica que los comprende; y su uso en el tratamiento de la hepatitis c. | |
| CL2014003462A1 (es) | Uso de compuestos aminotriazolopiridinas sustituidos, en el tratamiento de afecciones inflamatorias, autoinmunitarias, proliferativas, alergias, rechazo de trasplantes, entre otras; composicion farmaceutica que los comprende; combinacion farmaceutica. | |
| PT3177659T (pt) | Compostos contendo azoto, adequados para uso na preparação de poliuretanos | |
| JO3154B1 (ar) | عوامل مضادة لـ trpv4 | |
| CL2015001279A1 (es) | Compuestos derivados de piridina, inhibidores del transportador de uratos urat 1; composicion farmaceutica que los comprende; uso para el tratamiento o prevencion de enfermedades tales como gota, hiperuricemia, hipertensión, enfermedades renales, entre otras. | |
| CL2014000450A1 (es) | Compuestos derivados de n-(heteroarilmetil)-6-[(2-heteroarilciclopropil)metoxi]pririmidin-4-amina, inhibidores de pde10; composicion farmaceutica; y su uso para el tratamiento de un trastorno seleccionado de trastornos psicóticos, delirantes, entre otros. | |
| CL2015001724A1 (es) | Compuestos derivados de péptidos, agonistas de oxitocina; composicion farmaceutica; y su uso para en el tratamiento del autismo, estres, ansiedad, depresion, esquizofrenia,entre otros. |